Simple answer is "NOT POSSIBLE" as of my data search and interpretation of physiology. However, the research is like always changing.
My reasons to say "NO" include the below mentioned facts and evidence.
The normal role of CETP is to transfer esterified cholesterol from HDL to LDL/VLDL lipoproteins and thus causing an increase in LDL and decrease in HDL, which is not desirable as both HDL decrease and LDL increase are associated with atherosclerotic cardiovascular diseases. CETP is a glycoprotein associated with HDL and CETP levels are raised in subjects with hyperlipidemia. Among so many of the cholesterol lowering drugs especially with its highlighted side effects CETP inhibitors emerge as a hope to reverse this mechanism.
Coming to your question once cholesterol transportation is from HDL to LDL is blocked by CETP inhibitors then the possibility you have raised becomes minimal i.e.,” LDL concentrations to be reduced whilst HDL stays the same”. So I interpret this to be theoretical NO.
Secondly the first generation CETP inhibitors were associated with kind of hyperaldosteronism causing hypokalemia and high blood pressure and later generations showed no improvements in terms of reduction of CVD related mortality. So the drugs are not considered that useful by many means to be better than statins and incoming PCSK9 inhibitors.
Thirdly, I believe the concept of traditional LDL as sole villain and HDL as hero will also change over time as there are various subclasses within both groups. Small dense LDL particles seem to be the actual culprit in the LDL types.
Some genetic modifications though have been found to be better to reduce hypercholesterolemia but not very clear on that.
However, the research is ongoing and may be some positive output comes out of that but not yet as more promising data to support its use.
Some CETP inhibitors will raise HDL-choleserol and lower LDL-cholesterol; others, only raise HDL-choesterol. In neither case, with some exceptions, was there any effect on plaque.